Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Functional extracellular vesicles engineered with lipid-grafted hyaluronic acid effectively reverse cancer drug resistance.

Liu J, Ye Z, Xiang M, Chang B, Cui J, Ji T, Zhao L, Li Q, Deng Y, Xu L, Wang G, Wang L, Wang Z.

Biomaterials. 2019 Dec;223:119475. doi: 10.1016/j.biomaterials.2019.119475. Epub 2019 Sep 5.

PMID:
31520888
2.

Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.

Liu Y, Zhou C, Wei S, Yang T, Lan Y, Cao A, Yang J, Hou Y.

Colloids Surf B Biointerfaces. 2018 Oct 1;170:330-340. doi: 10.1016/j.colsurfb.2018.06.024. Epub 2018 Jun 18.

PMID:
29936386
3.

Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.

Wu Y, Zhang Y, Zhang W, Sun C, Wu J, Tang J.

Colloids Surf B Biointerfaces. 2016 Feb 1;138:60-9. doi: 10.1016/j.colsurfb.2015.11.041. Epub 2015 Nov 25.

PMID:
26655793
4.

Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.

Zhong Y, Zhang J, Cheng R, Deng C, Meng F, Xie F, Zhong Z.

J Control Release. 2015 May 10;205:144-54. doi: 10.1016/j.jconrel.2015.01.012. Epub 2015 Jan 14.

PMID:
25596560
5.

Multifunctionalized Micelles Facilitate Intracellular Doxorubicin Delivery for Reversing Multidrug Resistance of Breast Cancer.

Cao A, Ma P, Yang T, Lan Y, Yu S, Liu L, Sun Y, Liu Y.

Mol Pharm. 2019 Jun 3;16(6):2502-2510. doi: 10.1021/acs.molpharmaceut.9b00094. Epub 2019 Apr 30.

PMID:
30998372
6.

Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin.

Qiu L, Qiao M, Chen Q, Tian C, Long M, Wang M, Li Z, Hu W, Li G, Cheng L, Cheng L, Hu H, Zhao X, Chen D.

Biomaterials. 2014 Dec;35(37):9877-9887. doi: 10.1016/j.biomaterials.2014.08.008. Epub 2014 Sep 15.

PMID:
25201738
7.

Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.

Gu J, Fang X, Hao J, Sha X.

Biomaterials. 2015 Mar;45:99-114. doi: 10.1016/j.biomaterials.2014.12.030. Epub 2015 Jan 17.

PMID:
25662500
8.

Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution.

Liu Y, Sun J, Lian H, Cao W, Wang Y, He Z.

J Pharm Sci. 2014 May;103(5):1538-47. doi: 10.1002/jps.23934. Epub 2014 Mar 11.

PMID:
24619562
9.

Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.

Liu HN, Guo NN, Wang TT, Guo WW, Lin MT, Huang-Fu MY, Vakili MR, Xu WH, Chen JJ, Wei QC, Han M, Lavasanifar A, Gao JQ.

Mol Pharm. 2018 Mar 5;15(3):882-891. doi: 10.1021/acs.molpharmaceut.7b00793. Epub 2018 Feb 1.

PMID:
29357260
10.
11.

Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line.

Li J, Xu LZ, He KL, Guo WJ, Zheng YH, Xia P, Chen Y.

Breast Cancer Res. 2001;3(4):253-63. Epub 2001 Apr 2.

12.

The effect of dual-functional hyaluronic acid-vitamin E succinate micelles on targeting delivery of doxorubicin.

Wang J, Ma W, Guo Q, Li Y, Hu Z, Zhu Z, Wang X, Zhao Y, Chai X, Tu P.

Int J Nanomedicine. 2016 Nov 7;11:5851-5870. eCollection 2016.

13.

Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part I. Synthesis, characterization and in vitro investigation.

Negi LM, Talegaonkar S, Jaggi M, Verma AK, Verma R, Dobhal S, Kumar V.

Colloids Surf B Biointerfaces. 2014 Nov 1;123:600-9. doi: 10.1016/j.colsurfb.2014.09.062. Epub 2014 Oct 27.

PMID:
25454761
14.

Charge-reversal-functionalized PLGA nanobubbles as theranostic agents for ultrasonic-imaging-guided combination therapy.

Yang H, Shen X, Yan J, Xie X, Chen Z, Li T, Li S, Qin X, Wu C, Liu Y.

Biomater Sci. 2018 Aug 21;6(9):2426-2439. doi: 10.1039/c8bm00419f.

PMID:
30040100
15.

Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.

Wang J, Qu H, Jin L, Zeng W, Qin L, Zhang F, Wei X, Lu W, Zhang C, Liang W.

J Pharm Sci. 2011 Jun;100(6):2267-77. doi: 10.1002/jps.22461. Epub 2011 Jan 18.

PMID:
21246559
16.

Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.

Han M, Lv Q, Tang XJ, Hu YL, Xu DH, Li FZ, Liang WQ, Gao JQ.

J Control Release. 2012 Oct 28;163(2):136-44. doi: 10.1016/j.jconrel.2012.08.020. Epub 2012 Aug 23.

PMID:
22940126
17.

P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells.

Li R, Wu R, Zhao L, Wu M, Yang L, Zou H.

ACS Nano. 2010 Mar 23;4(3):1399-408. doi: 10.1021/nn9011225.

PMID:
20148593
18.

Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study.

Kobayashi E, Iyer AK, Hornicek FJ, Amiji MM, Duan Z.

Clin Orthop Relat Res. 2013 Mar;471(3):915-25. doi: 10.1007/s11999-012-2610-2.

19.

Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.

Tang J, Zhang L, Gao H, Liu Y, Zhang Q, Ran R, Zhang Z, He Q.

Drug Deliv. 2016 May;23(4):1130-43. doi: 10.3109/10717544.2014.990651. Epub 2014 Dec 10.

PMID:
25491241
20.

Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate.

Sivak L, Subr V, Tomala J, Rihova B, Strohalm J, Etrych T, Kovar M.

Biomaterials. 2017 Jan;115:65-80. doi: 10.1016/j.biomaterials.2016.11.013. Epub 2016 Nov 12.

PMID:
27886555

Supplemental Content

Support Center